Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Thiogenesis Therapeutics Corp V.TTI

Alternate Symbol(s):  TTIPF

Thiogenesis Therapeutics, Corp. is a Canada-based clinical-stage biopharmaceutical company. The Company is engaged in developing thiol-active therapeutic compounds, which are prodrugs used to treat unmet pediatric medical needs. The Company’s lead compound, TTI-0102, is a disulfide, made up of two thiols that lead to two independent cysteamine molecules. Cysteamine is a thiol that has been... see more

Recent & Breaking News (TSXV:TTI)

    Thiogenesis Announces Acceptance of Clinical Trial Application - Part I in the EU for MELAS

    Newsfile March 25, 2024

    Thiogenesis Announces Closing of Final Tranche in $4.5 Million Non-Brokered Private Placement

    Newsfile December 20, 2023

    Thiogenesis Announces Closing of Non-Brokered Private Placement of Common Shares and Insider Participation

    Newsfile December 18, 2023

    Thiogenesis CEO Invited to Lead a Round Table Discussion at Influential Mitochondria Symposium

    Newsfile December 4, 2023

    Thiogenesis Announces Addition of Dr. Vince Stanton Jr. to Its Scientific Advisory Board

    Newsfile November 27, 2023

    Thiogenesis Announces Non-Brokered Private Placement of Common Shares

    Newsfile November 20, 2023

    Thiogenesis Therapeutics Reports on Full Year 2022 Financial Results and Provides Corporate Update

    Newsfile May 10, 2023

    Thiogenesis Therapeutics (TSXV:TTI) grants stock options

    Azuka Onwuka December 9, 2022

    Thiogenesis Announces Stock Option Grants

    Newsfile December 9, 2022

    Thiogenesis Therapeutics (TSXV:TTI) closes $5.3M non-brokered private placement

    John Ballem  November 21, 2022

    Thiogenesis Announces Closing of Oversubscribed $5.3 Million Non-Brokered Private Placement

    Newsfile November 21, 2022

    Thiogenesis Therapeutics (TSXV:TTI) upsizes non-brokered private placement

    Azuka Onwuka November 2, 2022

    Thiogenesis Announces Increase in Offering Size for Non-Brokered Private Placement of Common Shares

    Newsfile November 2, 2022

    Thiogenesis (TSXV:TTI) announces non-brokered private placement

    Azuka Onwuka October 24, 2022

    Thiogenesis Announces Non-Brokered Private Placement of Common Shares

    Newsfile October 24, 2022

    Thiogenesis Adopts New Equity Incentive Plan

    Newsfile October 17, 2022

    Thiogenesis Announces Results from Annual and Special Meeting of Shareholders

    Newsfile September 26, 2022

    Thiogenesis Announces the Formation of its Scientific Advisory Board

    Newsfile August 30, 2022

    Thiogenesis Announces Positive Results from Phase 1 Dose-Escalation Study of its Lead Compound TTI-0102

    Newsfile May 18, 2022